Posts

Showing posts with the label Europe Rett Syndrome Market Analysis

Europe Rett Syndrome Market Analysis by Industry Perspective, Comprehensive Analysis, Growth and Forecast 2021 to 2028

Image
  The  rett syndrome  takes place due to mutation in MECP2 gene. The MECP2 gene encodes the methyl- CpG binding protein 2 and is located on the long arm of chromosome X. The arrival of  symptoms  arises with age. The infants with rett syndrome have normal growth for the first six months before any signs of the  disorder  are noticed. The frequent changes usually show up when the infants are between 12 and 18 months. The symptoms can be sudden or slow. Valproate, lamotrigine, and carbamazepine were the drugs used most frequently as monotherapy. Valproate monotherapy was highly effective as 75% of treated  patients  achieved seizure remission. Monotherapy with lamotrigine or carbamazepine was effective in half of the treated patients. However, the factors such as the rise in medical cost, strict regulatory framework, the complexity of rett syndrome are expected to hamper the growth of the Europe rett syndrome market. On the other hand, the upco...